New pill aims to melt liver fat in NASH patients

NCT ID NCT07198386

Recruiting now Disease control Sponsor: Cascade Pharmaceuticals, Inc Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new tablet called CS060380 for adults with non-alcoholic steatohepatitis (NASH), a serious fatty liver disease. About 120 participants will take either the drug or a placebo daily for 12 weeks. Researchers will measure changes in liver fat using MRI and track any side effects to see if the drug is safe and effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NASH are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatohepatitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NASH

Contacts and locations

Locations

Ruian People's Hosptial
RECRUITING

Wenzhou, Zhejiang, China
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
NOT_YET_RECRUITING

Shanghai, Shanghai Municipality, China
The Affiliated Hospital of Hangzhou Normal University
RECRUITING

Hangzhou, Zhejiang, 311121, China
The Fifth People's Hospital of Suzhou
RECRUITING

Suzhou, Jiangsu, China
The First Affiliated Hospital of Fujian Medical University
NOT_YET_RECRUITING

Fuzhou, Fujian, China
Xiamen Hospital of T.C,M.
RECRUITING

Xiamen, Fujian, China
Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine
NOT_YET_RECRUITING

Shanghai, Shanghai Municipality, China
Zhongshan Hospital Fudan University
RECRUITING

Shanghai, Shanghai Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.